Pathogenesis of liver fibrosis - PubMed (original) (raw)
Review
Pathogenesis of liver fibrosis
Virginia Hernandez-Gea et al. Annu Rev Pathol. 2011.
Abstract
Liver fibrosis is a major cause of morbidity and mortality worldwide due to chronic viral hepatitis and, more recently, from fatty liver disease associated with obesity. Hepatic stellate cell activation represents a critical event in fibrosis because these cells become the primary source of extracellular matrix in liver upon injury. Use of cell-culture and animal models has expanded our understanding of the mechanisms underlying stellate cell activation and has shed new light on genetic regulation, the contribution of immune signaling, and the potential reversibility of the disease. As pathways of fibrogenesis are increasingly clarified, the key challenge will be translating new advances into the development of antifibrotic therapies for patients with chronic liver disease.
Similar articles
- Cirrhosis--can we reverse hepatic fibrosis?
Tangkijvanich P, Yee HF Jr. Tangkijvanich P, et al. Eur J Surg Suppl. 2002;(587):100-12. Eur J Surg Suppl. 2002. PMID: 16144208 Review. - Liver fibrosis: searching for cell model answers.
Gutiérrez-Ruiz MC, Gómez-Quiroz LE. Gutiérrez-Ruiz MC, et al. Liver Int. 2007 May;27(4):434-9. doi: 10.1111/j.1478-3231.2007.01469.x. Liver Int. 2007. PMID: 17403182 Review. - Hepatic stellate cells and the reversal of fibrosis.
Kisseleva T, Brenner DA. Kisseleva T, et al. J Gastroenterol Hepatol. 2006 Oct;21 Suppl 3:S84-7. doi: 10.1111/j.1440-1746.2006.04584.x. J Gastroenterol Hepatol. 2006. PMID: 16958681 Review. - [Liver fibrosis in hepatitis B: a dynamic process].
Bedossa P. Bedossa P. Gastroenterol Clin Biol. 2010 Sep;34 Suppl 2:S103-8. doi: 10.1016/S0399-8320(10)70028-2. Gastroenterol Clin Biol. 2010. PMID: 21095512 French. - Hepatic fibrogenesis.
Guo J, Friedman SL. Guo J, et al. Semin Liver Dis. 2007 Nov;27(4):413-26. doi: 10.1055/s-2007-991517. Semin Liver Dis. 2007. PMID: 17979077 Review.
Cited by
- Nanogene editing drug delivery systems in the treatment of liver fibrosis.
Wang Q, Jia S, Wang Z, Chen H, Jiang X, Li Y, Ji P. Wang Q, et al. Front Med (Lausanne). 2024 Sep 25;11:1418786. doi: 10.3389/fmed.2024.1418786. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39386741 Free PMC article. Review. - C23 ameliorates carbon tetrachloride-induced liver fibrosis in mice.
Tang RX, Xie XJ, Xiong Y, Li S, Luo C, Wang YG. Tang RX, et al. World J Hepatol. 2024 Sep 27;16(9):1278-1288. doi: 10.4254/wjh.v16.i9.1278. World J Hepatol. 2024. PMID: 39351519 Free PMC article. - NADPH oxidase 4 deficiency promotes hepatocellular carcinoma arising from hepatic fibrosis by inducing M2-macrophages in the tumor microenvironment.
Kim JY, Kang W, Yang S, Park SH, Ha SY, Paik YH. Kim JY, et al. Sci Rep. 2024 Sep 27;14(1):22358. doi: 10.1038/s41598-024-72721-4. Sci Rep. 2024. PMID: 39333166 Free PMC article. - Pyroptosis in health and disease: mechanisms, regulation and clinical perspective.
Liu Y, Pan R, Ouyang Y, Gu W, Xiao T, Yang H, Tang L, Wang H, Xiang B, Chen P. Liu Y, et al. Signal Transduct Target Ther. 2024 Sep 20;9(1):245. doi: 10.1038/s41392-024-01958-2. Signal Transduct Target Ther. 2024. PMID: 39300122 Free PMC article. Review. - Effect of an Autotaxin Inhibitor, 2-(4-Chlorophenyl)-7-methyl-8-pentylimidazo[1,2-a] Pyrimidin-5(8_H_)-one (CBT-295), on Bile Duct Ligation-Induced Chronic Liver Disease and Associated Hepatic Encephalopathy in Rats.
Roy S, Chakrabarti M, Mondal T, Das TK, Sarkar T, Datta S, Kundu M, Banerjee M, Kulkarni OP. Roy S, et al. ACS Pharmacol Transl Sci. 2024 Aug 13;7(9):2662-2676. doi: 10.1021/acsptsci.4c00066. eCollection 2024 Sep 13. ACS Pharmacol Transl Sci. 2024. PMID: 39296254
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials